



CORRIGENDUM

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]

Al-Janabi A, Yiu ZZN. *Psoriasis (Auckl)*. 2022;12:1–14.

The authors have advised that there is an error in Table 1 on page 2. The text “IL-7A” in the Target column for the Ixekizumab row should read “IL-17A”.

The authors apologize for this error.

Psoriasis: Targets and Therapy downloaded from <https://www.dovepress.com/>
For personal use only.

Psoriasis: Targets and Therapy

Dovepress

Publish your work in this journal

Psoriasis: Targets and Therapy is international, peer-reviewed, open access journal focusing on psoriasis, nail psoriasis, psoriatic arthritis and related conditions, identification of therapeutic targets and the optimal use of integrated treatment interventions to achieve improved outcomes and quality of life. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/psoriasis-targets-and-therapy-journal>

<https://doi.org/10.2147/PTT.S380486>

Psoriasis: Targets and Therapy 2022:12 187

187

Received: 29 June 2022
Accepted: 29 June 2022
Published: 1 July 2022



© 2022 Al-Janabi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <https://www.dovepress.com/terms.php> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<http://creativecommons.org/licenses/by-nc/3.0/>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<https://www.dovepress.com/terms.php>).